Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Background/Aims Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response mechanisms remain a challenge. Methods Using data f...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee
Format:	Artigo
Jezik:	Inglês
Izdano:	Korean Association for the Study of the Liver 2024-10-01
Serija:	Clinical and Molecular Hepatology
Teme:	hepatocellular carcinoma immunotherapy atezolizumab bevacizumab transcriptome
Online dostop:	http://e-cmh.org/upload/pdf/cmh-2024-0333.pdf
Oznake:	Označite Brez oznak, prvi označite!